Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person10
Cardiff Oncology, Inc.
Company
CG Oncology, Inc.
Company
CITIUS ONCOLOGY, INC.
Company
Coherus Oncology, Inc.
Company
Kura Oncology, Inc.
Company
Pyxis Oncology, Inc.
Company
Aktis Oncology, Inc.
Company
CHAMPIONS ONCOLOGY, INC.
Company
Starling Oncology, Inc.
Company
ALX ONCOLOGY HOLDINGS INC
Company
Primary record5
Cardiff Oncology, Inc. filed 8-K
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On October 22, 2026, Dr. Roger Sidhu, Chief Medical Officer of Cardiff Oncology, Inc. (the “Company”) sepa
Cardiff Oncology, Inc. filed 8-K
Item 5.07 Submission of Matters to a Vote of Security Holders On October 22, 2026, Cardiff Oncology, Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”). A total of 48,084,246 shares of
Cardiff Oncology, Inc. filed 8-K
Item 1.01. Entry into a Material Definitive Agreement. On September 14, 2026, Cardiff Oncology, Inc. (the Company ) and Nerviano Medical Sciences, S.r.l. ( Nerviano ) entered into a Confidential Settlement Agreement and
Cardiff Oncology, Inc. filed DEF 14A
SEC form DEF 14A filed by Cardiff Oncology, Inc. (CIK 1213037) on 2026-08-26.
Cardiff Oncology, Inc. filed 8-K
Item 2.02 Results of Operations and Financial Condition. On August 11, 2026, Cardiff Oncology, Inc. issued a press release announcing a business update and financial results for the second quarter ended June 30, 2026. A